MonTa BioSciences Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
MonTa BioSciences General Information
Description
Developer of cancer immunotherapy designed to boost the immune system of cancer patients. The company's immunotherapy makes use of micelle-based nanoparticles with an agonist, which helps to stimulate immune cells to migrate into tumor tissue leading to tumor cell killing within hours, enabling medical professionals to recognize and eliminate the metastatic disease.
Contact Information
Website
www.montabiosciences.comCorporate Office
- Diplomvej 377
- 2800 Lyngby
- Denmark
Corporate Office
- Diplomvej 377
- 2800 Lyngby
- Denmark
MonTa BioSciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 8. Later Stage VC | 20-Oct-2022 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series A) | 31-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 6. Accelerator/Incubator | 01-Feb-2018 | Completed | Startup | |||
| 5. Early Stage VC | 10-Mar-2017 | Completed | Startup | |||
| 4. Accelerator/Incubator | 21-Sep-2016 | Completed | Startup | |||
| 3. Grant | Completed | Startup | ||||
| 2. Grant | 01-Aug-2014 | Completed | Startup | |||
| 1. University Spin-Out | 06-Jul-2014 | Completed | Startup |
MonTa BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
MonTa BioSciences Comparisons
Industry
Financing
Details
MonTa BioSciences Competitors (8)
One of MonTa BioSciences’s 8 competitors is Adcendo, a Venture Capital-Backed company based in Frederiksberg, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adcendo | Venture Capital-Backed | Frederiksberg, Denmark | ||||
| Symphogen | Formerly VC-backed | Ballerup, Denmark | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA |
MonTa BioSciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MonTa BioSciences Patents
MonTa BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260139063-A1 | Pre-medication and improved treatment regimen | Pending | 20-Oct-2022 | ||
| WO-2024083959-A1 | Pre-medication and improved treatment regimen | Inactive | 20-Oct-2022 | ||
| US-20240197759-A1 | Immune stimulating nanoparticle composition | Pending | 25-Mar-2021 | ||
| WO-2022200553-A2 | Immune stimulating nanoparticle composition | Inactive | 25-Mar-2021 | ||
| WO-2022200553-A3 | Immune stimulating nanoparticle composition | Inactive | 25-Mar-2021 | A61P35/00 |
MonTa BioSciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MonTa BioSciences Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Founder Group | Corporation | Minority | ||
| Consolidated Biosciences | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| Nordic Mentor Network For Entrepreneurship | Accelerator/Incubator | |||
| Novo Holdings | Venture Capital | Minority |
MonTa BioSciences FAQs
-
When was MonTa BioSciences founded?
MonTa BioSciences was founded in 2014.
-
Where is MonTa BioSciences headquartered?
MonTa BioSciences is headquartered in Lyngby, Denmark.
-
What is the size of MonTa BioSciences?
MonTa BioSciences has 7 total employees.
-
What industry is MonTa BioSciences in?
MonTa BioSciences’s primary industry is Drug Discovery.
-
Is MonTa BioSciences a private or public company?
MonTa BioSciences is a Private company.
-
What is MonTa BioSciences’s current revenue?
The current revenue for MonTa BioSciences is .
-
How much funding has MonTa BioSciences raised over time?
MonTa BioSciences has raised $17.1M.
-
Who are MonTa BioSciences’s investors?
Founder Group, Consolidated Biosciences, , Nordic Mentor Network For Entrepreneurship, and Novo Holdings are 5 of 6 investors who have invested in MonTa BioSciences.
-
Who are MonTa BioSciences’s competitors?
Adcendo, Symphogen, Damora Therapeutics ( Drug Discovery), Ayala Pharmaceuticals, and Aura Biosciences are some of the 8 competitors of MonTa BioSciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
